Epstein-Barr Virus (EBV) Vaccine Study

The Epstein-Barr Virus (EBV) is a very common and infectious virus in humans and is part of the herpes family. Infectious mononucleosis “mono” is the most common illness caused by EBV. EBV can spread bodily fluids such as blood, saliva, and semen. It can also spread through blood transfusions and organ transplantations. Typical symptoms, once infected with EBV include rash, fever, swollen lymph nodes in the neck and armpits, sore throat, extreme fatigue, head and body aches, and swollen liver, spleen, or both. Once infected with the virus, it will remain in your body and can reactivate if it is triggered. As you get older, the reactivation of the virus due to triggers can cause larger health problems such as cancer, multiple sclerosis, rheumatoid arthritis, and more.

There currently is no vaccine to prevent EBV. At Rochester Clinical Research we are currently conducting a study to evaluate an mRNA vaccine that will potentially prevent infections such as mono and other associated EBV diseases. The vaccine may also prevent later reactivation in the body due to the virus.

For this study, we are seeking volunteers between the ages of 12-55 years old to participate. The study is about 24 months long and includes 13 visits to our office with 16 telephone calls. Study-related care is available to participants at no cost and health insurance is not required nor needed. Compensation for time and travel is available to those who qualify.